Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for New Horizon Health's Median PS Value or its related term are showing as below:
HKSE:06606's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.7 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
New Horizon Health (HKSE:06606) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
New Horizon Health's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
14.14
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health Median PS Value Related Terms
New Horizon Health Median PS Value Historical Data
* Premium members only.
The historical data trend for New Horizon Health's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06606 vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, New Horizon Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Horizon Health Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, New Horizon Health's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where New Horizon Health's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. New Horizon Health's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$3.259.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Horizon Health (HKSE:06606) has a Median PS Value of HK$0.00 as of Jul. 23, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on New Horizon Health and its competitors.
Is New Horizon Health's Median PS Value too high?
New Horizon Health's current Median PS Value is HK$0.00. Overall, New Horizon Health has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does New Horizon Health's Median PS Value compare to ABT and SYK?
New Horizon Health's Median PS Value of HK$0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Median PS Value is 0.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on New Horizon Health and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. New Horizon Health's current Median PS Value is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Horizon Health stock overvalued right now?
New Horizon Health (HKSE:06606) has a current Median PS Value of HK$0.00. The current Median PS Value is HK$0.00. New Horizon Health's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For New Horizon Health (HKSE:06606), the current Median PS Value is HK$0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
New Horizon Health Ltd is engaged in early cancer screening and in-home testing in China. The company has an early detection and cancer screening-focused pipeline of five products and product candidates with an emphasis on colorectal cancer screening. The company focuses on cancer prevention and cure through screening and early detection. It generates maximum revenue from ColoClear and Pupu Tube products.
35GF Score
Get the complete analysis for HKSE:06606
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06606 has been successfully added to your 
